Tivic Health Systems Enters Equity Purchase Agreement

The latest announcement is out from Tivic Health Systems ( (TIVC) ).

On March 18, 2025, Tivic Health Systems entered into an Equity Purchase Agreement with Mast Hill Fund, allowing Tivic to sell up to $25 million in common stock over 24 months. This agreement provides Tivic with financial flexibility to support its strategic initiatives, including expanding its biopharmaceutical program and advancing its non-invasive cervical vagus nerve stimulation devices. The company also reported a 30% reduction in net loss for 2024, reflecting improved financial management. Tivic’s recent strategic moves, including acquiring rights to Entolimod™ and appointing new leadership, aim to enhance its market position and drive growth in the biotech sector.

More about Tivic Health Systems

Tivic Health Systems is a diversified therapeutics company focusing on harnessing the immune and autonomic nervous systems to combat disease and promote health. The company develops non-invasive medical devices, such as the FDA-approved ClearUP® for sinus pain, and is advancing its bioelectronic program with a focus on non-invasive vagus nerve stimulation. Additionally, Tivic is expanding into drug development with its biologic program, featuring the late-stage TLR5 agonist, Entolimod™, for treating acute radiation syndrome.

YTD Price Performance: -40.82%

Average Trading Volume: 748,896

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.93M

Learn more about TIVC stock on TipRanks’ Stock Analysis page.